Spartan Planning & Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$662K Buy
2,630
+229
+10% +$49.3K 0.44% 40
2026
Q1
$522K Sell
2,401
-1,241
-34% -$275K 0.39% 37
2025
Q4
$832K Buy
3,642
+258
+8% +$58.8K 0.61% 30
2025
Q3
$784K Buy
3,384
+1,735
+105% +$353K 0.61% 32
2025
Q2
$306K Sell
1,649
-1,365
-45% -$254K 0.26% 64
2025
Q1
$631K Buy
3,014
+1,574
+109% +$306K 0.61% 35
2024
Q4
$256K Buy
+1,440
New +$265K 0.23% 59
2023
Q4
$333K Buy
2,150
+1,606
+295% +$234K 0.36% 36
2023
Q3
$81.1K Buy
+544
New +$79.9K 0.1% 78
2022
Q4
$186K Buy
1,148
+311
+37% +$47.7K 0.23% 64
2022
Q3
$112K Sell
837
-552
-40% -$79.2K 0.15% 35
2022
Q2
$213K Buy
1,389
+780
+128% +$119K 0.28% 31
2022
Q1
$99K Buy
+609
New +$88.5K 0.12% 68

Other funds holding ABBV

Spartan Planning & Wealth Management's ABBV Position: Q2 2026 in Review

Spartan Planning & Wealth Management increased its AbbVie (ABBV) stake by 9.5% in Q2 2026, buying an estimated $49.3K and bringing the position to 2,630 shares worth $662K. The position accounts for 0.44% of the portfolio, ranked #40.

Spartan Planning & Wealth Management first reported a position in ABBV in Q1 2022 and has held it in 13 quarters since. The position peaked at $832K in Q4 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Spartan Planning & Wealth Management held 2,630 shares of AbbVie worth $662K as of Q2 2026.
  • Spartan Planning & Wealth Management bought 229 AbbVie shares in Q2 2026, an estimated $49.3K.
  • AbbVie made up 0.44% of Spartan Planning & Wealth Management's portfolio in Q2 2026, its #40 holding.
  • Spartan Planning & Wealth Management first reported a position in AbbVie in Q1 2022 and has held it in 13 quarters since.
  • Spartan Planning & Wealth Management's AbbVie position peaked at $832K in Q4 2025.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Spartan Planning & Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.